Want to see FR:ALDVI full AI Analyst Report?
Advicenne SA (ALDVI) AI Stock Analysis
Top Page
Advicenne SA
(Paris:ALDVI)
The score is driven down primarily by weak financial performance (persistent losses, cash burn, and negative equity) and bearish technicals (price below all key moving averages with negative MACD). Valuation provides limited support due to a very high P/E and no dividend yield data.
Advicenne SA (ALDVI) vs. iShares MSCI France ETF (EWQ)
- Market Cap
- EUR 9.42M
- Dividend Yield
- ―
- Average Volume (3M)
- 81.23K
- Price to Earnings (P/E)
- 217.1
- Beta (1Y)
- 0.62
- Revenue Growth
- 0.10%
- EPS Growth
- 99.69%
- Country
- France
- Employees
- 11
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Advicenne SA Business Overview & Revenue Model
Company Description
Advicenne S.A. operates as a specialized pharmaceutical firm, focusing on the innovation and commercialization of therapeutic solutions for various kidney-related disorders. The company's primary offering, Sibnayal, targets both distal renal tubular...
How the Company Makes Money
Advicenne primarily makes money from (1) sales of its marketed medicines and (2) commercialization agreements that monetize its products through partners in certain geographies. A key revenue stream is product revenue from Sibnayal (ADV7103) in marke...
Advicenne SA Financial Statement Overview
Summary
Overall financial quality is very weak: small and volatile revenue with a shift to negative growth in 2025, persistent operating and net losses, and ongoing cash burn. The balance sheet is a major risk with negative equity across 2022–2025, indicating a stressed capital structure and limited financial flexibility, despite some improvement in gross margin turning positive in 2025.
Income Statement
18Very NegativeBalance Sheet
12Very NegativeCash Flow
15Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.62M | 6.01M | 4.97M | 4.46M | 2.40M | 2.69M |
| Gross Profit | -4.75M | -922.00K | -1.18M | -6.31M | 1.28M | 1.72M |
| EBITDA | 2.45M | -7.81M | 1.35M | -6.23M | -9.70M | -12.02M |
| Net Income | 43.00K | -9.53M | -6.46M | -7.03M | -11.47M | -12.43M |
Balance Sheet | ||||||
| Total Assets | 7.54M | 7.14M | 9.51M | 12.41M | 14.26M | 18.88M |
| Cash, Cash Equivalents and Short-Term Investments | 1.55M | 1.34M | 3.25M | 5.25M | 8.32M | 12.69M |
| Total Debt | 21.18M | 19.00M | 18.19M | 18.32M | 18.75M | 12.54M |
| Total Liabilities | 29.16M | 33.51M | 28.58M | 24.38M | 24.88M | 18.57M |
| Stockholders Equity | -21.62M | -26.37M | -19.07M | -11.97M | -10.50M | 309.00K |
Cash Flow | ||||||
| Free Cash Flow | -4.11M | -4.11M | -853.00K | -7.27M | -9.26M | -12.82M |
| Operating Cash Flow | -3.73M | -3.73M | -762.00K | -5.99M | -9.15M | -12.53M |
| Investing Cash Flow | -403.00K | -403.00K | -108.00K | -1.32M | -2,000 | -395.00K |
| Financing Cash Flow | 2.23M | 2.23M | -1.13M | 4.23M | 4.78M | 8.85M |
Advicenne SA Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALDVI, the sentiment is Negative. The current price of 0.65 is below the 20-day moving average (MA) of 0.65, below the 50-day MA of 0.85, and below the 200-day MA of 1.36, indicating a bearish trend. The MACD of -0.05 indicates Negative momentum. The RSI at 39.45 is Neutral, neither overbought nor oversold. The STOCH value of 51.63 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:ALDVI.
Advicenne SA Peers Comparison
Overall Rating
FR:SIGHT46Neutral
FR:ALSEN45Neutral
FR:ALNEV43Neutral
FR:ABNX42Neutral- FR:ALDVI37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| FR:SIGHT | 46Neutral | EUR 18.98M | -1.06 | 52.39% | ― | -610.31% | 43.88% |
| FR:ALSEN | 45Neutral | EUR 87.32M | -2.04 | -54.15% | ― | ― | 6.26% |
| FR:ALNEV | 43Neutral | EUR 173.61K | 0.00 | -26.52% | ― | -44.46% | 100.00% |
| FR:ABNX | 42Neutral | EUR 70.84M | -7.32 | -80.82% | ― | -10.38% | -72.05% |
| FR:ALDVI | 37Underperform | EUR 9.42M | 217.14 | -0.18% | ― | 0.10% | 99.69% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| FR:ALDVI | Advicenne SA | 0.65 | -1.05 | -61.99% | |
| FR:SIGHT | GenSight Biologics | 0.08 | -0.05 | -38.89% | |
| FR:ABNX | ABIONYX Pharma SA | 1.62 | -2.39 | -59.63% | |
| FR:ALSEN | Sensorion SAS | 8.64 | -8.86 | -50.63% | |
| FR:ALNEV | Neovacs SA | 0.10 | -375.90 | -99.97% |
Advicenne SA Corporate Events
Advicenne Extends Financial Runway to 2028 with New Bond Tranche
Advicenne has received the remaining €1 million tranche of a bond financing agreement with a fund managed by L1 Capital, lifting its cash position and extending its financial runway from mid-2027 to 2028. The improved visibility is underpinned...
Advicenne swings to profit as Sibnayal growth and French pricing deals cut debt
Advicenne reported a sharp improvement in its first-half 2026 performance, turning a €4.62 million net profit versus a loss a year earlier, driven by price agreements for Sibnayal and Likozam in France and strong growth in Sibnayal sales across...
Advicenne Pulls U.S. Application for Rare Kidney Drug ADV7103 After FDA Feedback
Advicenne has voluntarily withdrawn its New Drug Application to the U.S. Food and Drug Administration for ADV7103 in primary distal renal tubular acidosis, after regulators indicated that additional Chemistry, Manufacturing and Controls work is requi...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 19, 2026